Initial Results from the CALGB 10801 Study
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).
Timothy S. Pardee, MD, Assistant Professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, describes initial results of the CALGB 10801 (Alliance) study, which added dasatinib to standard induction and consolidation therapy for newly diagnosed patients with core binding factor (CBF) acute myeloid leukemia (AML).
Clinical Pearls:
- This study looked at improving the outcomes of AML patients who have translocation between chromosomes 8 and 21 or an inversion of chromosome 16
- These patients generally do better than other AML patients, but their outcome is still worse compared to other hematologic malignancies
- The study added dasatinib, which has activity against c-Kit, in the hopes of improving survival
- Results found that dasatinib was a tolerable regimen and demonstrated reasonable and encouraging response rates
- This data is preliminary and more mature results are needed before conclusions are drawn
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
